GILD Stock Breaks 52-Week High 💥 | Trodelvy Data Shocks Wall Street! | $150 Coming Soon? скачать в хорошем качестве

GILD Stock Breaks 52-Week High 💥 | Trodelvy Data Shocks Wall Street! | $150 Coming Soon?

‪@WallStreetPulse01‬ GILD Stock Breaks 52-Week High 💥 | Trodelvy Data Shocks Wall Street! | $150 Coming Soon? Gilead Sciences (NASDAQ: GILD) just broke out to a new 52-week high after a powerful 4.21% rally, closing at $122.81 on October 17th, 2025. This isn’t just a random uptick — it’s a massive re-rating of Gilead’s entire story. For years, investors called Gilead the “HIV company,” but Friday’s surge proved that oncology is now the future. At the ESMO 2025 Congress, Gilead released groundbreaking data for Trodelvy, showing strong results in triple-negative breast cancer and new success in combination with Merck’s Keytruda. This is the data that could make Gilead the next major oncology leader. 💊 In this video, we break down: • Why Trodelvy’s Phase 3 ASCENT-03 results shocked analysts • Why institutional investors are loading up on GILD stock • How the oncology division is now driving real growth • What analysts are saying — new price targets: $135 to $143 • Whether this breakout signals a $150+ stock in 2026 This isn’t a short-term trade — this is a fundamental re-evaluation of one of America’s biggest biopharma giants. If you invest through Fidelity, SoFi, Robinhood, or Interactive Brokers, this video will help you understand why Gilead just became one of the most important biotech stories of 2025. 📈 Watch till the end — you’ll see why this move could redefine the company’s next decade. #GileadSciences #GILD #GILDStock #StockMarketNews #BiotechStocks #Trodelvy #ESMO2025 #Biopharma #PharmaStocks #Investing #StockMarketToday #NASDAQ #HealthcareStocks #StockMarketInvesting #FidelityInvestments #SoFiInvest #RobinhoodStocks #InteractiveBrokers #StockAnalysis #WallStreetNews Gilead Sciences stock, GILD stock, GILD stock price, GILD stock forecast, GILD stock prediction, GILD stock today, GILD stock news, Gilead stock analysis, Gilead Sciences analysis, Gilead stock forecast, Gilead stock update, Gilead stock today live, Gilead stock prediction 2025, Gilead stock price target, Gilead stock breakout, Gilead stock rally, Gilead stock surge, Gilead stock momentum, Gilead stock jump, Gilead stock live update, Gilead stock trend, Gilead stock recovery, Gilead stock earnings, Gilead stock results, Gilead stock performance, Gilead Sciences earnings, Gilead Sciences news, Gilead Sciences update, Gilead Sciences stock live, Gilead Sciences forecast 2025, Gilead Sciences stock prediction, Gilead Oncology news, Gilead Trodelvy, Trodelvy data, Trodelvy drug results, Gilead Trodelvy 2025, Gilead ESMO 2025, Gilead ESMO update, Gilead Oncology pipeline, oncology breakthrough 2025, Trodelvy breast cancer data, Gilead Immunomedics, Gilead acquisition, Gilead Chugai, Gilead Trodelvy Keytruda, Gilead cancer therapy, Gilead oncology division, Gilead drug approval, FDA approval Gilead, Gilead pharma, Gilead biotech, Gilead health innovation, biotech stocks 2025, top biotech stocks USA, healthcare innovation stocks, pharma stocks 2025, pharmaceutical stocks USA, healthcare sector stocks, healthcare growth stocks, pharma growth stocks, healthcare investing USA, Gilead investing, Gilead investment opportunity, long term Gilead stock, Gilead stock for long term, best dividend stocks USA, dividend growth stocks, healthcare dividend stocks, Gilead dividend yield, Gilead dividend payout, Gilead Sciences financials, Gilead valuation, Gilead market cap, Gilead revenue growth, Gilead profit, Gilead pipeline update, Gilead R&D, Gilead innovation, Gilead HIV portfolio, Gilead antiviral drugs, Gilead hepatitis portfolio, Gilead oncology strategy, Gilead Trodelvy sales, Gilead stock catalyst, Gilead catalyst 2025, biotech investing USA, healthcare innovation USA, top healthcare stocks 2025, biotech rally USA, pharma rally, USA pharma stocks, USA biotech news, biotech stock surge, pharma stock update, Gilead investor update, Gilead Wall Street news, Gilead analyst upgrade, Gilead stock buy rating, Gilead price target $150, Gilead bullish outlook, Gilead stock bull run, Gilead stock upside, Gilead stock resistance, Gilead stock breakout level, Gilead stock chart, Gilead technical analysis, Gilead support and resistance, Gilead stock volume spike, Gilead institutional buying, Fidelity biotech stocks, SoFi biotech investing, Robinhood biotech stocks, Interactive Brokers biotech analysis, Nasdaq biotech index, biotech industry 2025, Gilead Sciences future, Gilead growth forecast, Gilead competitive advantage, Gilead oncology growth, Trodelvy breast cancer success, Gilead drug data, Gilead oncology expansion, Trodelvy sales forecast, Gilead 2025 outlook, Gilead 2026 prediction, Gilead future value, Gilead stock future potential, top healthcare investments, biotech stock to buy now, pharma stock to buy now, Gilead best pharma stock, Gilead multibagger potential, Gilead long-term buy, Gilead top pick USA, Wall Street stocks, biotech breakthrough 2025, cancer therapy innovation, Gilead news today, biotech research USA